Core 1: Non-human primate core

核心1：非人类灵长类核心

• 批准号: 10360195
• 负责人: Guido Silvestri
• 金额: $ 40.04万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-24 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10360195
• 关键词: Core; Non; human; primate; core

ABSTRACT – Nonhuman Primate (NHP) Core (Core 1, Leader: Dr. Guido Silvestri, Yerkes National Primate Research Center, Emory University) The most appropriate animal model to define the origin, kinetics, and impact of humoral and cellular immune- based strategies on viral rebound in infants following postnatal HIV-1 infection and treatment is simian immunodeficiency virus (SIV)/simian-human immunodeficiency virus (SHIV) infection of rhesus macaques. Indeed, this model is particularly well-suited for our proposed studies because pediatric models of postnatal transmission have been developed and used to define the pathogenesis of infant HIV-1 infection and prevention strategies. However, NHP studies require extensive infrastructure and unique expertise. Thus, we the Program's Nonhuman Primate (NHP) Core (Core 1) will coordinate and implement all the NHP experiments proposed by the Program's two Projects: Project 1: “Origin and predictors of viral rebound in infants”, (PI: Dr. Ann Chahroudi, Emory University), and Project 2: “Impact of immune-based intervention on viral rebound in orally SHIV-infected infant monkeys” (PI: Dr. Genevieve Fouda, Duke University). The Core will support the Program through the following Specific Aims: Aim 1 - Organize, coordinate, and conduct studies of infant SHIV reservoir and rebound; Aim 2 - Administer and monitor antiretroviral treatment (ART) in orally SHIV-infected infant monkeys; and Aim 3 - Perform pharmacokinetic analysis of polyclonal antibody infusions in infant macaques to determine the dose and administration interval for treatment of infant SHIV infection. Led by Dr. Guido Silvestri, the NHP Core will ensure the following that are essential to the successful completion of these projects: 1) adherence to regulatory procedures relevant to research with NHPs; 2) coordination and implementation of all animal-related procedures, including housing, immunizations of infants, nursery-rearing of infants, antiretroviral treatments, and sample collections for weekly viral load measurement and monthly blood counts; 3) proper storage and/or shipment of samples to the Projects and Cores; and 4) maintenance of a database of clinical health parameters. Dr. Silvestri will ensure all NHP supported research efforts are tightly integrated and that evolving needs of the research projects will be met. As an integral component of this Program, the NHP Core will provide critical support to achieve the shared goals of understanding the source, kinetics, and impact of immune interventions on HIV-1 rebound in postnatally infected infants.

摘要-非人灵长类动物（NHP）核心（核心1，领导人：Yerkes National的Guido Silvestri博士 埃默里大学灵长类动物研究中心） 确定体液和细胞免疫的起源、动力学和影响的最合适的动物模型- 基于出生后HIV-1感染和治疗的婴儿病毒反弹的策略是类似的 免疫缺陷病毒（SIV）/猴-人免疫缺陷病毒（SHIV）感染。 事实上，这种模型特别适合我们提出的研究，因为产后的儿科模型 已经开发出并用于定义婴儿HIV-1感染的发病机制， 预防战略。然而，NHP研究需要广泛的基础设施和独特的专业知识。因此我们 该计划的非人类灵长类动物（NHP）核心（核心1）将协调和实施所有的NHP实验 由该计划的两个项目提出：项目1：“婴儿病毒反弹的起源和预测因素”，（PI：Dr. Ann Chahroudi，埃默里大学）和项目2：“免疫干预对病毒反弹的影响， 经口感染SHIV的幼猴”（PI：Genevieve Fouda博士，杜克大学）。核心将支持 通过以下具体目标制定计划：目标1 -组织、协调和开展婴儿SHIV研究 目标2 -在经口感染SHIV的患者中实施和监测抗逆转录病毒治疗 目的3 -在婴儿中进行多克隆抗体输注药代动力学分析 猕猴，以确定治疗婴儿SHIV感染的剂量和给药间隔。博士领导 NHP核心Guido Silvestri将确保以下事项对于成功完成这些任务至关重要 项目：1）遵守与NHP研究相关的监管程序; 2）协调和 执行所有与动物有关的程序，包括住房、婴儿免疫接种、托儿所饲养、 婴儿，抗逆转录病毒治疗，每周病毒载量测量和每月血液样本采集 计数; 3）适当储存和/或运送样品到项目和岩心;以及4）维护 临床健康参数数据库。Silvestri博士将确保所有NHP支持的研究工作都紧密地 综合并满足研究项目不断变化的需求。作为其中的一个组成部分， 计划，NHP核心将提供关键的支持，以实现共同的目标，了解源， 动力学和免疫干预对出生后感染婴儿HIV-1反弹的影响。